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Abstract The mammalian p34 cdc2 protein kinase, a universal cell 
cycle regulator, complements cdc21CDC28 temperature-sensitive 
mutations in yeasts. We report the biochemical characterisation 
of two substitutions of human cdc2 at lysine 33, a residue involved 
in nucleotide binding, that differently alter the fission yeast cell 
cycle. K33A-bsedc2 and K33R-hscdc2 mutants are both catalyti- 
cally inactive, but overexpression of K33R-cdc2 is lethal while 
K33A-cdc2 is not. We show that human K33R-cdc2 acts as a 
dominant negative allele that associates yeast cdcl31cycfinB and 
therefore renders endogeneons Schizosaccharomyces pombe cdc2 
unactivatable. These results are discussed on the light of the 
molecular modeling of the mutants in the cdc2 model structure. 
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I. Introduction 
The cdc2 protein kinase is the prototype of an expanding 
family of enzymes called cyclin-dependent kinases (cdk) that 
play essential regulatory functions at the major control points 
of the cell cycle. Originally identified in yeasts as an essential 
gene required for both G1/S and G2/M transitions, cdc2/ 
CDC28 is present in every eukaryotic organism examined [1]. 
In vertebrates, the cdc2 protein kinase is involved in the regula- 
tion of entry into mitosis, whereas the control of cell prolifera- 
tion at GI/S is regulated by the related cyclin-dependent 
kinases. The periodic activation of cyclin-dependent kinases is 
tightly regulated by at least four highly conserved biochemical 
mechanisms (reviewed in [2]). Binding to the cyclin regulatory 
subunit is required for the activation of the catalytic subunit. 
However, tight interaction and complete activation requires 
phosphorylation  a conserved threonine residue (T161 in 
human) [2,3]. Activation of cdc2 is also coincident with 
dephosphorylation on tyrosine 15, a residue located within the 
nucleotide binding site. Finally, inhibitors of cyclin-dependent 
kinases have also recently been identified and are likely to play 
essential regulatory functions in the control of cell proliferation 
[4]. Mutational analysis of cdc2 is providing some important 
clues toward the understanding of the molecular basis of cyclin 
interaction with cdk [5-8] and a number of residues implicated 
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in that interaction have been identified [6,9]. Their involvement 
in the regulation of cdc2 activity has been strenghtened from 
the modeling of cdc2 based on the structure of cAMP depend- 
ent protein kinase [6]. Comparison of the X-ray structures of 
free cdk2 [10] and of the cyclinA-bound cdk2 complex [11] 
showed the large conformational changes and the realigning of 
the active site residues that occurs in the kinase upon cyclin A 
binding. Here, we report he differential effects of overexpres- 
sion of human cdc2 lysine 33 mutants on the fission yeast cell 
cycle. We discuss these data in the context of their predicted 
effects on cdc2 structure and function. 
2. Materials and methods 
2.1. Yeast strains, cultures, microscopy and flow cytometry 
The Schizosaccharomyces pombe strain used in this study is SP199 (h + 
leul-32 ura4 ade210). Cells were cultured and transformed asdescribed 
[12] with pREP41 plasmids [13] encoding the wild type or the mutant 
human cdc2 sequences. The promoter was kept under epressed condi- 
tions by addition of 4 pM thiamine to the growth medium and 
derepressed asdescribed [13-15]. Cytological observations were per- 
formed as described [16]. Flow cytometry was carried out on a Facscan 
(Becton Dickinson) following the protocol described in [16]. 
2.2. Mutagenesis 
Oligonucleotide-directed mutagenesis of the human cdc2 coding se- 
quence was performed as described [17]. Mutations were screened and 
checked by DNA sequencing. 
2.3. Kinase assays 
Yeast cell extracts and immunoprecipitations were performed exactly 
as described [12]. Polyclonal antibodies raised against human cdc2 
carboxy-terminal sequence (G6), recombinant cdcl3/cyclin B (a gift 
from J. Hyams) and a monoclonal nti-human cdc2 (a gift from J. 
Lukas) were used. The kinase assay reactions were carried out in the 
presence of2/lg histone H1 (Boehringer Mannheim), 10/IM cold ATP 
and 2.5/~Ci of [y-32p]ATP for 5 min at 30°C. Histone H1 phosphoryl- 
ation was quantified after electrophoresis, excision from the gel and 
counting. 
2.4. Immunoblot analyses 
Cell lysates or immunoprecipitates w re electrophoresed, transfered 
onto Hybond C membrane as described [18]. Immunodetections were 
performed using the above mentioned antibodies with specific HRP 
conjugated antibodies (Bio-Rad) and enhanced chemiluminescence de- 
tection (NEN). 
2.5. Molecular modeling 
The cdc2 coordinates were kindly provided to us by S. Taylor and 
E. Radzio-Andzelm (UCSD, La JoUa). The structure was displayed on 
an Evans and Sutherland ESV/30-33. Molecular modeling was done 
using the program O [21] and minimization by X-PLOR (Brunger, 
A.T., X-PLOR version 3.1, Yale University Press, New-Haven, CT) 
was run on a digital DEC 3000/400 Alpha workstation (96 Mb RAM). 
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3. Results 
3.1. Effect of human cdc2 lysine 33 mutant overexpression  cell 
growth 
The human cdc2 (hscdc2) cDNA was mutated using site- 
directed mutagenesis n order to change lysine 33, a residue 
conserved in every kinase that has been shown to be essential 
for the catalytic activity, into alanine or arginine. The effects 
of these two mutations on the biochemical properties of hscdc2 
were investigated in vivo after transfection i to wild type fission 
yeast. Regulated expression of wild type and mutant cdc2 pro- 
teins was achieved using the nmtl  regulatable promoter that is 
derepressed within 15 to 18 h after removal of thiamine from 
the culture medium. 
As shown in Fig. 1A, overexpression of both K33A and 
K33R hscdc2 mutants proteins impaired yeast proliferation 
rate. However, while the proliferation of cell overexpressing 
K33R mutation was totally inhibited, K33A mutation only led 
to a 50% inhibitory effect on fission yeast growth as compared 
to the strain overexpressing wild-type human cdc2. 
The phenotypic effects of hscdc2 lysine 33 mutants and wild 
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Fig. l. (A) Effects of cdc2 lysine 33 mutations on fission yeast growth 
rate. Fission yeast strains carrying plasmids encoding wild-type human 
cdc2 (open squares) and mutants K33A-cdc2 and K33R-cdc2 (open 
triangles and open circles, respectively) were grown under promoter 
repressing conditions (with 4 pM thiamine), then resuspended in thia- 
mine-free media at time 0. Cells were counted at intervals. (B) Pheno- 
types of S. pombe cells overexpressing lysine 33 cdc2 mutants. Cells 
transformed with plasmids encoding wild type hscdc2 or mutants were 
cultured in the absence of thiamine for 30 h. (Left panel) wild-type 
human cdc2, (middle panel) K33R-cdc2, (right panel) K33A-cdc2. 
Fixed cells are stained with 4'-6-diamidino-2-phenylindole (DAPI). 
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Fig. 2. DNA content analysis of the cells measured by flow cytometry. 
Cells were cultured in the absence of thiamine for 0, 25, 30 and 40 h. 
DNA content was determined by flow cytometry after propidium io- 
dide staining. In cells grown with thiamine (time 0) the major peak 
correspond to cells having a 2C DNA content. 
type overexpression were then examined microscopically (Fig. 
1B) after 30 h of thiamine removal, i.e. about 12 h of cdc2 
protein overexpression. Cells overexpressing wild type hscdc2 
were slightly smaller than untransformed cells, displaying a 
'semi-wee' phenotype (Fig. 1B, left panel). This effect is likely 
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Fig. 3. Protein kinase activity associated with human cdc2 and yeast cdcl3-cyclin B. Strains transformed with plasmids allowing the overexpression 
of wild-type human cdc2 (light gray bars) and mutants K33A-cdc2 and K33R-cdc2 (gray and black bars respectively) were grown under promoter 
repressing conditions, then resuspended in media without hiamine at time 0. At intervals, samples were collected and cell lysates were processed 
to an immunoprecipitation. (A) Human cdc2 was immunoprecipitated with an antibody specific to the carboxy terminal human cdc2 (a gift from 
G. Draetta) and the associated kinase activity toward histone H 1 was determined (a.u. arbitrary units). (B) S. pombe cdc 13-cyclin B was immunopre- 
cipitated with a polyclonal serum raised against the cdcl 3 recombinant protein (a gift from J. Hyams). The associated kinase activity toward histone 
H1 was quantified and is shown as a percentage of the activity before induction of the human cdc2 protein (at time 0). 
to be due to the overall increase in cdc2 kinase activity (see 
below). Cells overexpressing K33R and K33A mutant proteins 
displayed an elongated phenotype as compared to wild type. 
K33R-hscdc2 and K33A-hscdc2 average cell sizes after 12 h of 
protein overexpression were 16/~m and 30/ lm respectively. 
While the overexpression f K33R-hscdc2 led to a typical 'cdc'- 
cell cycle arrest phenotype (Fig. 1 B, middle panel), in the case 
of K33A the cells continuated to divide although at longer size 
(Fig. 1 B, right panel). A flow cytometry analysis of the cellular 
DNA content was performed in order to investigate the cell 
cycle distribution of the cells overexpressing wild type and K33 
hscdc2 mutants (Fig. 2). In exponentially growing untrans- 
formed S. pombe cells, G1 phase is usually not detectable be- 
cause it represents less than 10% of the cell cycle duration. 
Overexpression of wild-type hscdc2 led to a progressive in- 
crease in the percentage of cell displaying a 1C DNA content 
(44% after 40 h). This reflects the shortening of the G2-phase 
and the subsequent relative increase in Gl-phase length that is 
necessary to reach the minimum size required to enter S-phase. 
The small peak (about 5% of the cells) that was also detected 
after the 2C peak is likely to be due to the cells that are already 
undergoing S-phase while cytokinesis is still unfinished, a nor- 
mal feature of exponentially growing fission yeast cell. K33A- 
hscdc2 overexpression had no noticeable ffect on the distribu- 
tion of the cells in G1- and G2-phases even after a long induc- 
tion time. However, in the case of K33R-hscdc2, thirty h after 
thiamine removal, a 4C DNA content peak was clearly visible. 
After 40 h three peaks representing 8%, 50% and 42% of the 
cells, and corresponding to 1C, 2C and 4C DNA content re- 
spectively, were detected. 
The consequences of K33R-hscdc2 overexpression on the 
cell cycle distribution with the occurrence of a 4C DNA content 
peak in mononucleated cells (see Fig. 1 B) were reminiscent of 
the effect of cyclin B disruption on the unscheduled entry in 
S-phase [19], and prompted us to examine in details the bio- 
chemical properties of this mutant. 
3.2. Effect of human cdc2 lysine 33 mutants on cdc2 kinase 
activities 
The kinase activities associated with the overexpressed 
hscdc2 and with the endogenous fission yeast cdc2 were both 
examined. Overexpression of wild type or of the two hscdc2 
mutants was induced by thiamine removal and yeast cells were 
collected at intervals. In the three strains, the level of induction 
of the human cdc2 protein kinase was very similar (see below, 
Fig. 4B). The kinases activity of the human cdc2 was assayed 
after immunoprecipitation with a specific anti peptide anti- 
body. As shown in Fig. 3A, the activity of overexpressed wild 
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Fig. 4. Interaction ofcdc2 lysine 33 mutants with cdc 13/cyclin B. Strains 
transformed with plasmids allowing the overexpression of wild-type 
human cdc2 and mutants K33A-cdc2 and K33R-cdc2 were grown 
under promoter repressing conditions, resuspended in media without 
thiamine (time 0), and samples were collected at 25 h and 30 h. (A and 
B) 100 #g of total ysates of cells collected at 30 h were subjected to the 
immunodetection of human cdc2 (A) and S. pombe cdcl3 (B) with a 
monoclonal ntibody raised against human cdc2 (a gift from J. Lukas) 
and a with a polyclonal antibody (a gift from J. Hyams), respectively. 
(C) Cell lysates (2 mg) were subjected to immunoprecipitation with 
anti-cdcl3 antibody and then blotted with monoclonal anti human 
cdc2. 
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Fig. 5. Structural effect of the K33R mutation in the cdc2 model structure. Stereo view of the part of the N-terminal lobe of the cdc2 kinase in the 
active conformation. The steric hindrance created by the arginine side-chain at position 33 may be released by a 1.1 A rigid body movement of the 
PSTAIRE helix ~1 (thick ribbon). This movement affects the loop region at the N-terminal part of helix ~1 that bears residues implicated in cyclin 
binding. A salt-bridge interaction is formed between R33 and E51 (in thick line in the mutant model). 
type human cdc2 was high at about 25 h following thiamine 
removal. It thereafter declined to about 25% of the maximal 
level. Since this progressive inhibition paralleled the increase in 
the level of the overexpressed c c2 protein (data not shown), 
this indicates that the amount of active cdc2/cdcl3 (cyclin B) 
complex was decreasing in the immunoprecipitate. This effect 
might be explained by the fact that cyclin B was becoming 
progressively limiting as regard to the amount of available cdc2. 
No kinase activity toward histone H 1 was detected in the anti- 
human cdc2 immunoprecipitates p rformed from lysates of the 
strains overexpressing K33A- and K33R-hscdc2 mutants, indi- 
cating that these two mutants were catalytically inactive. The 
kinase activity associated with cdcl3-cyclin B immunoprecipi- 
tates was also measured in these strains at different ime after 
promoter elease and was examined as a percentage of the 
activity before the induction of the human cdc2 protein overex- 
pression (Fig. 313). In the strain overexpressing wild type 
human cdc2, a 5- to 8-fold increase of the total kinase activity 
associated with cdcl 3 was detected and might explain the 'semi- 
wee' phenotype of these cells. In the strain overexpressing 
K33A-hscdc2, the level of cdcl3-associated kinase was fairly 
constant confirming that K33A mutant protein had no activity 
and was unable to interfere with the activity of endogenous 
S. pompe cdc2-cdcl3 complexes. In the case of K33R-hscdc2 
mutant overexpression, we observed a progressive decrease in 
the total evel ofcdcl 3-associated kinase, that dropped to about 
15% and 10% of the initial activity after 30 and 40 h of overex- 
pression, respectively. This last result suggested that this cata- 
lytically inactive mutant was also able to negatively interfere 
with the activity of the endogenous cdc2/cdcl3 kinase com- 
plexes. 
3.3. K33 R-hscdc2 mutant associates cdc l 3-cyclin B in a inactive 
complex 
To analyse the molecular basis of the differential effects of 
the K33-hscdc2 mutations, we examined the in vivo interaction 
of these mutant proteins with endogenous fission yeast cyclin 
B (the cdcl3 gene product). After 30 h without thiamine, the 
level of induction of wild type, K33A and K33R hscdc2 were 
similar (Fig. 4A) as was the level of endogenous cdcl 3-cyclin B 
(Fig. 4B). At this time point, the association of K33A-hscdc2 
protein with cdcl3 was comparable to the wild-type, whereas 
the K33R-hscdc2 mutant protein was at least 3.5-fold (as 
judged by scanning densitometry) more abundant (Fig. 4C). 
From this experiment it can be suggested that the K33R-hscdc2 
mutant protein binds strongly to the cdcl3/cyclin B in an inac- 
tive and possibly stabilised complex, making the regulatory 
subunit unaccessible to S. pombe cdc2. 
3.4. Molecular modeling of the K33R-cdc2 mutant 
The interactions observed for the catalytic triad (Lys33, 
Glu51, Asp145) in the crystal structure of the cyclinA-bound 
cdk2 complex [11] were found to be essentially identical to those 
observed in the catalytically active PKA structure from which 
a cdc2 model was derived [6]. This model, kindly provided by 
S.S. Taylor and E. Radzio-Andzelm, was therefore used to 
analyse the possible ffects of the K33R substitution. 
Mutation of lysine 33 to an arginine residue lead to steric 
conflicts which may, obviously, be overcome in the mutant 
protein as overexpression in fission yeast was successful. From 
the structural observations, it seemed that the steric constraints 
may be released in two different ways. The guanidinium group 
of R33 could move towards D145, inducing a sequential rear- 
rangement olD145, N132 and D127 that would strongly affect 
ATP binding and catalysis. However, the positional shifts 
would be restricted to this area and, if they may explain the lack 
of activity, would not suggest how cyclin B binding is affected. 
On the other hand, the steric constraints introduced by the 
K33R substitution could be released through a rigid body dis- 
placement of helix ~ 1 (the PSTAIRE helix) (Fig. 5). This would 
maintain and strengthen the salt-bridge interaction between 
residue 33 and glutamic 51 when the lysine is substituted for an 
arginine. The movement of this helix is of small amplitude (1.1 
A) and will also likely affect he conformation of the loop 3842 
whose residues are implicated in cyclin binding to cdc2. The 
K33R-cdc2 mutant protein would thus adopt a slightly differ- 
ent local conformation i  an area that seems critical with re- 
spect o both the properties of the catalytic triad and to cyclin 
binding. Introduction of an arginine residue at position 33, by 
promoting the formation of a strong R33-E51 salt-bridge inter- 
action, may lock the cdc2 protein in a conformation similar to 
that found in the cdk2-cyclinA complex. 
4. Discussion 
We report here the differential effects of overexpression f
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two human cdc2 lysine 33 mutant proteins in the fission yeast 
S. pombe. We show that both K33A-cdc2 and K33R-cdc2 are 
catalytically inactive and inhibit cell proliferation, however, the 
latter mutant behaves as a dominant negative allele. Three 
experimental sets of data suggest hat K33R-cdc2 might act 
through the sequestration of the mitotic B-cyclin. First, 
whereas the cells were mononucleate, the cell cycle distribution 
after K33R-hscdc2 overexpression desplayed a 4C DNA peak 
that might reflect he occurrence of a round of DNA replication 
in the absence of cell division. A similar observation was re- 
cently made in cells in which the cyclin B gene was disrupted 
[19]. Second, we found that overexpressed K33R-cdc2 was as- 
sociated with cdc 13/cyclinB to a higher level than was wild type 
hscdc2. Third, and probably as a consequence of the binding 
of cdcl3/cyclinB to K33R-cdc2, the overall cellular cdcl3/cy- 
clin B associated kinase activity was inhibited. We propose that 
the K33R mutant of cdc2 is titrating cdcl3/cyclinB away from 
S. pombe cdc2, therefore mimicking the loss of cdc 13 function. 
What are the molecular effects of these mutations that could 
explain the enhanced interaction with cyclin and the different 
behavior of the K33A and K33R mutants of cdc2 in vivo? 
Lysine 33 is a nearly invariant amino acid across all the protein 
kinase family [20] and is involved in ATP binding by anchoring 
its ~- and fl-phosphate groups. The structure of the cyclinA- 
bound cdk2 complex [11] revealed a significant translation and 
rotation of the cdk2 PSTAIRE helix (helix ~1, residues 44 55) 
when compared to free cdk2 [10], leading to the formation of 
the K33-R51 interaction. This movement is accompanied by a 
conformational change of the preceding loop (residues 38~,2) 
which bears residues implicated in cyclin A binding to cdc2. 
Charged-to-alanine scanning mutagenesis of human cdc2 has 
shown that cyclin A binding is inhibited by mutations in several 
clusters of residues in the N-terminal lobe [6,9]. Residues E38, 
E40, E41 and E42, play essential roles in the specificity of cdk 
and cyclin interactions (our unpublished results). Assuming 
that the conformational changes in cdc2 upon cyclin B binding 
are essentially similar to those observed in cdk2 in the cdk2- 
cyclin A complex [11], molecular modelling suggests that the 
K33R mutation may, through the R33-E51 salt-bridge, lock 
the cdc2 molecule in a conformation where the association with 
cdcl3/cyclin B is favored. This appealing hypothesis in good 
agreement with the immunoprecipitation experiments where it 
was found that the amount of K33R-hscdc2 mutant associated 
with cdcl3/cyclinB was most abundant. An inactive complex 
with cdc 13/cyclin B would therefore be stabilised, arresting the 
cell cycle and rendering the cell functionally identical to cyclin 
B disruptant. The mutation of lysine 33 by an alanine residue 
has no such structural effect. Removal of a functional group 
considered to be essential in catalysis will lead to an inactive 
enzyme, in which one of the key molecular events (the forma- 
tion of the K33-E51 interaction) linked to cyclin binding can- 
not occur. There would be therefore no consequence on the 
affinity of cyclin B to the K33A-cdc2 mutant protein, related 
to the fact that this mutant protein do not interfere with the 
activity of endogeneous S. pombe cdc2-cyclin complexes. Struc- 
ture determination of both cdc2 and lysine 33 mutant protein 
monomeric and in complex with cyclin B would be required to 
investigate further these proposal. 
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